We are live on
!
Find out more
SL
Siren LLC Portfolio holdings
AUM
$3.61B
1-Year Est. Return
203.3%
This Fund
S&P 500
This Quarter
Est. Return
+36.54%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.35B
AUM Growth
+$796M
(+31%)
Cap. Flow
+$176M
Cap. Flow
% of AUM
5.24%
Top 10 Holdings %
Top 10 Hldgs %
46.31%
Holding
141
New
26
Increased
29
Reduced
24
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$59.1M |
| 2 |
Olema Pharmaceuticals
OLMA
|
+$58.7M |
| 3 |
Zymeworks
ZYME
|
+$36.6M |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$29M |
| 5 |
Mineralys Therapeutics
MLYS
|
+$28.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$57.3M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$56M |
| 3 |
Rezolute
RZLT
|
+$45.8M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$31.6M |
| 5 |
Dyne Therapeutics
DYN
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.02% |
| 2 | Technology | 3.72% |
| 3 | Communication Services | 1.9% |
| 4 | Real Estate | 0.59% |
| 5 | Consumer Discretionary | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Zymeworks
ZYME
$1.69B
| $44.2M | 1.32% |
+1,680,121
| New | +$36.6M |
|
27
Solid Biosciences
SLDB
$777M
| $43.4M | 1.29% |
7,690,405
+274,500
| +4% | +$1.49M |
|
28
Wave Life Sciences
WVE
$1.14B
| $41.6M | 1.24% |
2,450,000
-1,246,322
| -34% | -$12.7M |
|
29
Xenon Pharmaceuticals
XENE
$6.36B
| $36.4M | 1.09% |
812,761
| – | – |
|
|
DBVT
30
DBV Technologies
DBVT
$823M
| $35.6M | 1.06% |
+1,857,362
| New | +$29M |
|
31
Erasca
ERAS
$6.55B
| $32.6M | 0.97% |
8,757,249
| – | – |
|
32
enGene Therapeutics
ENGN
$118M
| $30.1M | 0.9% |
+3,336,264
| New | +$26.7M |
|
33
Trevi Therapeutics
TRVI
$2.57B
| $28.6M | 0.85% |
2,286,867
-250,000
| -10% | -$2.89M |
|
34
Spyre Therapeutics
SYRE
$8.69B
| $26.8M | 0.8% |
818,598
+450,000
| +122% | +$11.8M |
|
|
35
Mineralys Therapeutics
MLYS
$2.4B
| $25.4M | 0.76% |
+699,999
| New | +$28.1M |
|
36
Denali Therapeutics
DNLI
$3.74B
| $23.1M | 0.69% |
1,396,513
+575,000
| +70% | +$9.71M |
|
37
Remitly
RELY
$4.77B
| $22.3M | 0.67% |
1,618,271
| – | – |
|
38
Fulcrum Therapeutics
FULC
$249M
| $22.1M | 0.66% |
+1,950,000
| New | +$19.8M |
|
|
RAPP
39
Rapport Therapeutics
RAPP
$2.01B
| $21.5M | 0.64% |
708,469
-345,000
| -33% | -$9.55M |
|
|
SLN
40
Silence Therapeutics
SLN
$570M
| $17.7M | 0.53% |
2,911,438
| – | – |
|
41
IHS Holding
IHS
$2.77B
| $17.6M | 0.52% |
2,357,520
| – | – |
|
42
Gossamer Bio
GOSS
$97.5M
| $16.1M | 0.48% |
5,208,968
| – | – |
|
|
UPB
43
Upstream Bio Inc
UPB
$348M
| $16M | 0.48% |
588,450
-200,000
| -25% | -$4.98M |
|
|
BCYC
44
Bicycle Therapeutics
BCYC
$276M
| $14.3M | 0.43% |
2,012,752
| – | – |
|
45
Monopar Therapeutics
MNPR
$739M
| $13.9M | 0.41% |
+212,298
| New | +$17.3M |
|
46
Cullinan Oncology
CGEM
$1.07B
| $12.4M | 0.37% |
1,193,410
| – | – |
|
|
SION
47
Sionna Therapeutics
SION
$2.05B
| $12.3M | 0.37% |
300,000
-25,000
| -8% | -$948K |
|
48
Inhibikase Therapeutics
IKT
$369M
| $12M | 0.36% |
+5,850,000
| New | +$9.31M |
|
|
NBP
49
NovaBridge Biosciences American Depositary Shares
NBP
$206M
| $11.9M | 0.36% |
3,000,000
+1,834,043
| +157% | +$8.12M |
|
50
Amazon
AMZN
$2.49T
| $11.9M | 0.35% |
51,500
-7,000
| -12% | -$1.6M |
|
Similar funds
U
WB
SPC
SCM
ACM
GCM
VI
JFG
Siren LLC's Q4 2025 Portfolio in Review
As of Q4 2025, Siren LLC held 141 positions worth $3.35B, up 31% from $2.56B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Siren LLC deployed $176M of net new capital in Q4 2025, opening 26 new positions and adding to 29 existing holdings. Its largest new stake was Olema Pharmaceuticals: 3,300,700 shares worth $82.5M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Arrowhead Research, an estimated $57.3M trimmed.
- Siren LLC's largest Q4 2025 buy was Olema Pharmaceuticals: 3,300,700 shares worth $82.5M.
- Siren LLC added most to Scholar Rock in Q4 2025, an estimated $59.1M increase.
- Siren LLC's biggest Q4 2025 reduction was Arrowhead Research, cutting an estimated $57.3M.
- Siren LLC fully exited Avidity Biosciences in Q4 2025, selling an estimated $56M.
- Siren LLC's ten largest holdings make up 46% of its $3.35B portfolio in Q4 2025.
- Siren LLC opened 26 new positions and closed 28 in Q4 2025.
- Siren LLC's portfolio value rose 31% quarter-over-quarter to $3.35B.
Based on Siren LLC's 13F filing for Q4 2025, filed 13 Feb 2026.